PT  - JOURNAL ARTICLE
AU  - Magnus Bäck
AU  - Sven-Erik Dahlén
AU  - Jeffrey M. Drazen
AU  - Jilly F. Evans
AU  - Charles N. Serhan
AU  - Takao Shimizu
AU  - Takehiko Yokomizo
AU  - G. Enrico Rovati
TI  - International Union of Basic and Clinical Pharmacology. LXXXIV: Leukotriene Receptor Nomenclature, Distribution, and Pathophysiological Functions
AID  - 10.1124/pr.110.004184
DP  - 2011 Sep 01
TA  - Pharmacological Reviews
PG  - 539--584
VI  - 63
IP  - 3
4099  - http://pharmrev.aspetjournals.org/content/63/3/539.short
4100  - http://pharmrev.aspetjournals.org/content/63/3/539.full
SO  - Pharmacol Rev2011 Sep 01; 63
AB  - The seven-transmembrane G protein-coupled receptors activated by leukotrienes are divided into two subclasses based on their ligand specificity for either leukotriene B4 or the cysteinyl leukotrienes (LTC4, LTD4, and LTE4). These receptors have been designated BLT and CysLT receptors, respectively, and a subdivision into BLT1 and BLT2 receptors and CysLT1 and CysLT2 receptors has been established. However, recent findings have also indicated the existence of putative additional leukotriene receptor subtypes. Furthermore, other ligands interact with the leukotriene receptors. Finally, leukotrienes may also activate other receptor classes, such as purinergic receptors. The aim of this review is to provide an update on the pharmacology, expression patterns, and pathophysiological roles of the leukotriene receptors as well as the therapeutic developments in this area of research.